Pira et al._Supplementary Tables and autoimmune Bullous Diseases Study Group

Supplementary files (Tables and List of participants to Autoimmune Bullous Diseases Study Group) related to the published paper on The Journal of American Academy of Dermatology titled "Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delay"与发表于《美国皮肤病学会杂志》的论文相关的补充材料（含表格及自身免疫性大疱性疾病研究小组的参与者名单），该论文题为："利格列汀是与BP180-NC16A/BP230血清阴性相关的大疱性类天疱疮的危险因素且病情更轻微：一项支持ECD-BP180酶联免疫吸附试验（ELISA）缩短诊断延迟的前瞻性病例对照研究证据"